Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pacific Neuroscience Medical Group
mi
from
Oxnard, CA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pacific Neuroscience Medical Group
mi
from
Oxnard, CA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Desert Valley Research
mi
from
Rancho Mirage, CA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Desert Valley Research
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pacific Research Network
mi
from
San Diego, CA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pacific Research Network
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Sharp Mesa Vista Hospital
mi
from
San Diego, CA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Sharp Mesa Vista Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Apex Research Institute
mi
from
Santa Ana, CA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Apex Research Institute
mi
from
Santa Ana, CA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
California Neuroscience Research
mi
from
Sherman Oaks, CA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
California Neuroscience Research
mi
from
Sherman Oaks, CA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
New England Institute for Clinical Research
mi
from
Stamford, CT
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
New England Institute for Clinical Research
mi
from
Stamford, CT
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Christiana Care Research Institute
mi
from
Newark, DE
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Christiana Care Research Institute
mi
from
Newark, DE
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Neuropsychiatric Research Center of Southwest Florida
mi
from
Fort Myers, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Neuropsychiatric Research Center of Southwest Florida
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Sunrise Clinical Research, Inc.
mi
from
Hollywood, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Sunrise Clinical Research, Inc.
mi
from
Hollywood, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Suncoast Clinical Research, Inc.
mi
from
New Port Richey, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Suncoast Clinical Research, Inc.
mi
from
New Port Richey, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Axiom Research
mi
from
Tampa, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Axiom Research
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Atlanta Center for Medical Research
mi
from
Atlanta, GA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
United Osteoporosis Center
mi
from
Gainesville, GA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
United Osteoporosis Center
mi
from
Gainesville, GA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Indiana University School of Medicine
mi
from
Indianapolis, IN
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Indiana University School of Medicine
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Cotton O'Neil Clinic
mi
from
Topeka, KA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Cotton O'Neil Clinic
mi
from
Topeka, KA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates, LLC
mi
from
Wichita, KA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pharmasite Research
mi
from
Baltimore, MD
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pharmasite Research
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Sheppard Pratt Health System
mi
from
Baltimore, MD
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Sheppard Pratt Health System
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
QUEST Research Institute
mi
from
Farmington Hills, MI
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
QUEST Research Institute
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Hattiesburg Clinic
mi
from
Hattiesburg, MS
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Hattiesburg Clinic
mi
from
Hattiesburg, MS
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
ClinVest
mi
from
Bolivar, MO
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
ClinVest
mi
from
Bolivar, MO
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Professionals
mi
from
Chesterfield, MO
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Professionals
mi
from
Chesterfield, MO
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Millenium Psychiatric Associates LLC
mi
from
Creve Coeur, MO
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Millenium Psychiatric Associates LLC
mi
from
Creve Coeur, MO
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Las Vegas Medical Research
mi
from
Las Vegas, NV
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Las Vegas Medical Research
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Advanced Memory Research Institute of New Jersey
mi
from
Toms River, NJ
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Advanced Memory Research Institute of New Jersey
mi
from
Toms River, NJ
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Bio Behavioral Health
mi
from
Toms River, NJ
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Bio Behavioral Health
mi
from
Toms River, NJ
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Albany Medical College
mi
from
Albany, NY
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Albany Medical College
mi
from
Albany, NY
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Richmond Behavorial Associates
mi
from
Staten Island, NY
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Richmond Behavorial Associates
mi
from
Staten Island, NY
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Alzheimer's Memory Center
mi
from
Charlotte, NC
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Alzheimer's Memory Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Piedmont Medical Research, LLC.
mi
from
Winston-Salem, NC
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Piedmont Medical Research, LLC.
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
University of Cincinnati Medical Center
mi
from
Cincinnati, OH
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
University of Cincinnati Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Neurology Diagnostics, Inc
mi
from
Dayton, OH
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Neurology Diagnostics, Inc
mi
from
Dayton, OH
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Insight Clinical Trials
mi
from
Shaker Heights, OH
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Insight Clinical Trials
mi
from
Shaker Heights, OH
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Lehigh Valley Hospital
mi
from
Allentown, PA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Lehigh Valley Hospital
mi
from
Allentown, PA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Lehigh Center for Clinical Research
mi
from
Allentown, PA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Lehigh Center for Clinical Research
mi
from
Allentown, PA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Trial Center, LLC, Psychiatry
mi
from
Jenkintown, PA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Trial Center, LLC, Psychiatry
mi
from
Jenkintown, PA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Rhode Island Mood & Memory Research Institute
mi
from
East Providence, RI
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Rhode Island Mood & Memory Research Institute
mi
from
East Providence, RI
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Butler Hospital
mi
from
Providence, RI
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Butler Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Houston Methodist
mi
from
Houston, TX
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Houston Methodist
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Services Center - Houston
mi
from
Houston, TX
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Services Center - Houston
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
The Memory Clinic
mi
from
Bennington, VT
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
The Memory Clinic
mi
from
Bennington, VT
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Sensible Healthcare
mi
from
Ocoee, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Sensible Healthcare
mi
from
Ocoee, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Xenoscience Inc.
mi
from
Phoenix, AZ
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Xenoscience Inc.
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Mile High Research Center
mi
from
Denver, CO
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Mile High Research Center
mi
from
Denver, CO
Click here to add this to my saved trials